Selected antiretroviral and anti-tuberculosis drug combinations by non-covalent bonding
| dc.contributor.advisor | Samsodien, Halima | |
| dc.contributor.author | Ngilirabanga, Jean Baptiste | |
| dc.date.accessioned | 2021-08-16T09:15:50Z | |
| dc.date.accessioned | 2024-05-15T07:16:51Z | |
| dc.date.available | 2021-08-16T09:15:50Z | |
| dc.date.available | 2024-05-15T07:16:51Z | |
| dc.date.issued | 2021 | |
| dc.description | Doctor Pharmaceuticae - DPharm | en_US |
| dc.description.abstract | Treatment of the human immunodeficiency virus (HIV) and tuberculosis (TB) infections have become very complicated due to the advent of drug resistance. Drug combinations offer an alternative approach to reducing the emergence of drug resistance. Pharmaceutical co-crystals have provided the pharmaceutical industry with the ability to optimise the physicochemical properties of active pharmaceutical ingredients (APIs) while preserving the biological activity. Pharmaceutical co-crystals are formed between APIs and suitable co-formers that are biologically safe or even a second or third API. | en_US |
| dc.identifier.uri | https://hdl.handle.net/10566/15059 | |
| dc.language.iso | en | en_US |
| dc.publisher | University of Western Cape | en_US |
| dc.rights.holder | University of Western Cape | en_US |
| dc.subject | HIV/AIDS | en_US |
| dc.subject | Tuberculosis | en_US |
| dc.subject | Infectious diseases | en_US |
| dc.subject | Drug resistance | en_US |
| dc.subject | Solid dispersions | en_US |
| dc.title | Selected antiretroviral and anti-tuberculosis drug combinations by non-covalent bonding | en_US |